Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on &lt;i&gt;KRAS/NF1&lt;/i&gt; Mutational Status. This evidence concerns the gene MAP2K7 and ovarian carcinoma.